Perceive Pharma: $15 Million (Series A) Raised For Advancing Ophthalmic Neuroprotection
By Amit Chowdhry ● Feb 24, 2025
Perceive Pharma, a pharmaceutical company that is pioneering novel small molecule therapeutics in ophthalmology, announced the closing of a $15 million Series A funding round, including Deerfield Management, Johnson & Johnson (through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc.), Braidwell LP, GV, the Retinal Degeneration Fund, and Catalio Capital Management, LP. Perceive Pharma was spun out from Perceive Biotherapeutics to accelerate the development of novel neuroprotective therapeutics in glaucoma and other indications. The company also brought in Carol Gallagher, Pharm.D., to the Perceive Pharma Board as an independent Board Director.